CDMO

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

By Editor's Desk
24 July 2026

Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.

Business CDMO Healthcare & Pharmaceuticals

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

By BiotechReality Business Intelligence Desk
24 April 2026

Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.

Category: CDMO

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

Areas Covered

Discover More

Gilead Accelerates Global Access Strategy for Gilead Once-Yearly Lenacapavir in HIV Prevention Push

Novo – Anthropic Claude Science Partnership Targets Faster Drug Discovery

Amgen IMDELLTRA Monitoring Time Cut to 6-8 Hours as FDA Approves Label Update for ES-SCLC

Novo Nordisk Rebrand: Company Unveils ‘Novo’ Name and ‘Lasting Health Starts Now’ Platform

Johnson & Johnson RYBREVANT Amivantamab NSCLC Regimen Delivers Longest Reported Survival in EGFR Exon 20 Lung Cancer

AstraZeneca Enhertu DESTINY-Lung04 Trial Demonstrates 14.3-Month Median PFS in First-Line HER2-Mutant NSCLC